In today’s briefing:
- China Healthcare Weekly (Jan.26)- Stocks Best Buying Point, Tragic PD-L1, Tiantan Biological Product
- Samsung Biologics (207940 KS): Stellar Performance in 4Q23; Outlook Remains Strong
- Mirati Therapeutics: Initiation of Coverage – Inside the Strategy Poised to Skyrocket KRAZATI’s Market Share in 2023! – Major Drivers
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
China Healthcare Weekly (Jan.26)- Stocks Best Buying Point, Tragic PD-L1, Tiantan Biological Product
- Even good enterprises could be neglected by the market, leading to low valuation. Many people wonder when is the best buying point for pharmaceutical companies. We shared our views.
- If PD-1 sold in China can still achieve a certain scale, the situation of PD-L1 is not the same. In fact, we’re pessimistic about all companies selling PD-L1 in China.
- Beijing Tiantan Biological Products (600161 CH) is a good defensive target in unfriendly external environment. The reasonable market value is RMB45-50 billion. We think Tiantan will maintain stable growth ahead.
Samsung Biologics (207940 KS): Stellar Performance in 4Q23; Outlook Remains Strong
- Samsung Biologics (207940 KS) reported 11% YoY growth in revenue to KRW1.07 trillion in 4Q23 driven by the ramp-up of operation of its Plant 4 and robust sales backlog.
- The company closed 2023 with record high revenue and operating profit, bucking the weakening trend in overall global CDMO sector.
- The outlook remains strong, with resilient business performance expected to drive a 10–15% annual growth in revenue for 2024.
Mirati Therapeutics: Initiation of Coverage – Inside the Strategy Poised to Skyrocket KRAZATI’s Market Share in 2023! – Major Drivers
- This is our first report on Mirati Therapeutics Inc., a pharmaceutical firm specializing in cancer treatment.
- The company has shown significant potential with a robust pipeline and innovative programs targeting areas of cancer with large unmet needs.
- In this report, we have carried out a fundamental analysis of the historical financial statements of the company.